1350749-64-2

Basic information

• Product Name: Carbamic acid, N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]-, 1,1-dimethylethyl ester
• CAS NO: 1350749-64-2
• Molecular Formula: C14H17F2NO2
• Molecular Weight: 269.291
• Mol File: 1350749-64-2.mol

Chemical Properties

• CAS DataBase Reference: Carbamic acid, N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]-, 1,1-dimethylethyl ester(1350749-64-2)
• EPA Substance Registry System: Carbamic acid, N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]-, 1,1-dimethylethyl ester(1350749-64-2)

Safety Data

• Hazardous Substances Data: 1350749-64-2(Hazardous Substances Data)

Upstream product

• 1006614-49-8 (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 220352-36-3 trans-(1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid 
• 1459720-02-5 (1R,2S)-2-(3,4-difluorophenyl)cyclopropanoic acid methyl ester 
• 1459720-05-8 (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarbohydrazide 
• 75-65-0 tert-butyl alcohol 
• 378236-67-0 (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarbonyl azide 
• 1215969-79-1 3-chloro-1-(3',4'-difluorophenyl)-propan-1-one 
• 1345413-26-4 trans-(1R,2S)-2-(3,4-difluorophenyl)-1-nitrocyclopropane 
• 1345413-25-3 (1S)-1-(3,4-difluorophenyl)-3-nitropropan-1-ol 
• 376608-71-8 trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine (2R)-2-hydroxy-2-phenylacetic acid salt 
• 367-11-3 ortho-difluorobenzene 

Downstream Products

• 1383715-58-9 tert-butyl (6-chloro-5-nitro-2-(propylthio)pyrimidin-4-yl)((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)carbamate 
• 274693-26-4 [3aR-[3aα,4α,6α,(1R,2S),6aα]]-2-[6-[[[7-(2-(3,4-difluorophenyl)cyclopropyl)]amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenteno-1,3-dioxolan-4-yl]oxy]ethanol 
• 274693-27-5 ticagrelor 
• 1383715-59-0 2-[[(3aR,4S,6R,6aS)-6-[[4-[N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-yl]-N-tert-butoxycarbonyl]amino]-2-(propylthio)-5-nitropyrimidin-6-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy] ethanol 
• 1402222-66-5 trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine hydrochloride 
• 1006614-49-8 (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine 
• 1427524-43-3 tert-butyl ((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)(3-((1R,2S,3S,4S)-2,3-dihydroxy-4-(2-hydroxyethoxy)cyclopentyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)carbamate 
• 1451195-45-1 tert-butyl (5-nitro-6-(((1R,2S,3S,4S)-2,3-dihydroxy-4-(2-hydroxyethoxy)cyclopentyl)amino)-2-(propylthio)pyrimidin-4-yl)((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)carbamate 
• 1451196-00-1 tert-butyl ((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)(6-(((1R,2S,3S,4S)-2,3-dihydroxy-4-(2-hydroxyethoxy)cyclopentyl)amino)-5-nitro-2-(propylthio)pyrimidin-4-yl)carbamate 
• 1427523-82-7 methyl 2-(((3aR,4S,6R,6aS)-6-(7-((tert-butoxycarbonyl)((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)acetate 
• 1427523-80-5 tert-butyl (5-amino-6-(((3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)amino)-2-(propylthio) pyrimidin-4-yl)((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)carbamate 
• 1427523-79-2 tert-butyl ((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)(6-(((3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)amino)-5-nitro-2-(propylthio)pyrimidin-4-yl)carbamate 
• 1383715-64-7 2-({(3aR,45,6R,6aS)-6-[7-{[[N-(1R,2S)-2-(3,4-difluorophenyl)-cyclopropan-1-yl]-N-tert-butoxycarbonyl]amino}-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}oxy)-O-tertbutoxycarbonylethanol 
• 1383715-63-6 C₃₀H₃₄F₂N₆O₄S 

Relevant articles and documents

Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors

Tranylcypromine (TCP)-based structural modifications lead to the discovery of new LSD1 inhibitors, of which compounds 26b and 29b effectively inhibit LSD1 with the IC50 values of 17 and 11 nM, respectively and also show good selectivity over MAO-B. Mechanistic studies showed that compound 29b concentration-dependently induced H3K4me1/2 accumulation in LSD1 overexpressed MGC-803 cells and also inhibited metastasis of MGC-803 cells. Collectively, both compounds could be promising lead compounds for further investigation.

General Cyclopropane Assembly by Enantioselective Transfer of a Redox-Active Carbene to Aliphatic Olefins

Asymmetric cyclopropane synthesis currently requires bespoke strategies, methods, substrates, and reagents, even when targeting similar compounds. This approach slows down discovery and limits available chemical space. Introduced herein is a practical and versatile diazocompound and its performance in the first unified asymmetric synthesis of functionalized cyclopropanes. The redox-active leaving group in this reagent enhances the reactivity and selectivity of geminal carbene transfer. This effect allowed the asymmetric cyclopropanation of various olefins, including unfunctionalized aliphatic alkenes, that enables the three-step total synthesis of (?)-dictyopterene A. This unified synthetic approach delivers high enantioselectivities that are independent of the stereoelectronic properties of the functional groups transferred. Our results demonstrate that orthogonally differentiated diazocompounds are viable and advantageous equivalents of single-carbon chirons.

A method for preparing for standard auspicious Luo river

The invention provides a ticagrelor preparation method. The method using a compound of structural formula 2 as an initiator comprises the following steps: 1, reacting the compound of structural formula 2 with di-tert-butyl pyrocarbonate to obtain a compound of structural formula 3; 2, reacting the compound of structural formula 3 with a compound of structural formula 4 to obtain a compound of structural formula 5; 3, reacting the compound of structural formula 5 with a compound of structural formula 6 to obtain a compound of structural formula 7; and 4, carrying out nitro group reduction on the compound of structural formula 7, cyclizing, and carrying out protective group removal to obtain ticagrelor of structural formula 1.

Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts

The present invention relates to the field of organic synthesis and describes the synthesis of specific intermediates suitable for the preparation of triazolopyrimidine compounds such as ticagrelor.

Synthesis of Triazolopyrimidine Compounds

The present invention relates to the filed of organic synthesis and describes the synthesis of specific triazolopyrimidine compounds and intermediates thereof as well as related derivatives, suitable for the preparation of ticagrelor (TGC)

SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS

The present invention relates to the field of organic synthesis and describes the synthesis of specific triazolopyrimidine compounds and intermediates thereof as well as related derivatives, suitable for the preparation of Ticagrelor (TCG).

SYNTHESIS OF 2-(3,4-DIFLUOROPHENYL)CYCLOPROPANAMINE DERIVATIVES AND SALTS

The present invention relates to the field of organic synthesis and describes the synthesis of specific intermediates suitable for the preparation of triazolopyrimidine compounds such as ticagrelor.

NOVEL PROCESSES FOR PREPARING TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF

Provided herein is a novel process for the preparation of triazolo[4,5-d]pyrimidine derivatives. Provided particularly herein is a novel, commercially viable and industrially advantageous process for the preparation of highly pure ticagrelor or a pharmaceutically acceptable salt thereof. Provided further herein is a novel process for the preparation of substituted cyclopentanamine derivatives, which are useful intermediates in the preparation of triazolo[4,5-d]pyrimidine compounds. Provided particularly herein is a novel, commercially viable and industrially advantageous process for the preparation of a ticagrelor intermediate, 2-[[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d] [1,3]- dioxol-4-yl]oxy]- 1 -ethanol.